Novo Nordisk (NVO)

• Market cap: $337B
• 1 day: 1.47%
• 5 days: -14.12%
• 1 month: -3.73%
• 3 months: -29.04%
• 6 months: -44.61%
• Year to date: -13.29%
• 1 year: -43.15%
• 5 years: 167.60%
• 10 years: 218.87%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Employees: 76,302

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

6% more call options, than puts

Call options by funds: $1.28B | Put options by funds: $1.21B

0.09% less ownership

Funds ownership: 10.03% [Q3] → 9.94% (-0.09%) [Q4]

8% less repeat investments, than reductions

Existing positions increased: 585 | Existing positions reduced: 637

8% less funds holding

Funds holding: 1,764 [Q3] → 1,624 (-140) [Q4]

25% less capital invested

Capital invested by funds: $40.2B [Q3] → $30.1B (-$10.2B) [Q4]

33% less first-time investments, than exits

New positions opened: 193 | Existing positions closed: 287

49% less funds holding in top 10

Funds holding in top 10: 61 [Q3] → 31 (-30) [Q4]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $105 38% upside
• Avg. target: $105 38% upside
• High target: $105 38% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

BMO Capital Evan David Seigerman 37% 1-year accuracy 7 / 19 met price target

38% upside $105

Outperform Maintained

23 Dec 2024